You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimum Dose of rhCC10 for Lung Protection in IRDS

    SBC: CLARAGEN, INC.            Topic: N/A

    DESCRIPTION (Scanned from the applicant's description): The proposed study involves an evaluation of the dose response to recombinant human CC10 in the preterm lamb, a surfactant-dependent model of neonatal/infant respiratory distress syndrome (IRDS). The preterm lamb model was used in the clinical development of artificial surfactants for the treatment of I ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. An Expanded Genetic Information System

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): The DNA alphabet is not limited to the four standard nucleotides. Rather, twelve nucleobases forming six base pairs joined by mutually exclusive hydrogen bonding patterns are possible within the geometry of the Watson-Crick base pair. These form An Expanded Genetic Information System (AEGIS), a new, "rule based" molecular re ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. Functional Genomics Software

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): A substantial commercial potential exists for software tools that allow a biomedical research scientist to use genomic data to form experimentally testable hypotheses. These will be used to exploit genomic sequence data to understand the aetiology of disease, to improve diagnostic tools, and to develop more effective therapies. T ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Neonatal Chest Phantom for Computed Radiography Testing

    SBC: Gammex, Inc.            Topic: N/A

    This proposal's long-term goal is to develop radiographic phantoms to address the following critical needs in the emerging field of digital x- ray imaging: quality control procedures for daily operations; quality assurance methods for users to evaluate products, perform acceptance testing and determine optimum system operating parameters; development tools for manufacturers to test new hardware an ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. Preparation of a Quantitative Apoptosis Imaging Agent

    SBC: NAVISCAN PET SYSTEMS, INC.            Topic: N/A

    This proposal addresses development of new imaging technology for noninvasive quantitative measurement of apoptosis in vivo. Apoptosis is genetically defined cell death. Understanding the role of apoptosis is critical to the development of new molecular-based therapeutic modalities. An apoptosis-imaging agent could be used to modify therapy for cancer patients, and to monitor cardiac transplant pa ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Development of basic tools for Cancer Research

    SBC: PROTEIN RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to produce active recombinant proteins involved in cancer progression and other important cellular processes. Recombinant proteins in biomedical research have now become an essential tool to study many aspects of cellular biology. Genes coding for several important cellular function such as tumor suppres ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government